Working… Menu

Ph II CHOP+Velcade in Mediastinal LBCL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00361621
Recruitment Status : Terminated (Closed due to slow accrual)
First Posted : August 8, 2006
Last Update Posted : December 3, 2012
Brigham and Women's Hospital
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Ann S. LaCasce, MD, Dana-Farber Cancer Institute

Brief Summary:
The main purpose of this study is to begin to collect information and try to learn whether or not VELCADE, when added to standard chemotherapy with CHOP/Rituxan, works in treating patients mediastinal large B-cell lymphoma. Recent research has shown that this type of lymphoma shares features with Hodgkin's lymphoma, including the importance of a particular pathway in the tumor cells called the NF-kB pathway. VELCADE works in part by blocking this pathway.

Condition or disease Intervention/treatment Phase
Non-Hodgkin's Lymphoma Drug: bortezomib Drug: Rituximab Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristine Drug: Prednisone Radiation: Radiation therapy Phase 2

Detailed Description:
  • This is a single arm phase 2 study of CHOP/Rituxan plus VELCADE followed by involved field radiotherapy designed to evaluate the complete response to chemotherapy as determined by PET scan following six cycles of therapy. One cycle equals 21 days.
  • For each cycle, on Day 1, the patient will receive VELCADE intravenously, followed by rituxan, and then followed by CHOP chemotherapy. Before receiving these drugs, the patient will be given standard medications (Tylenol, Benadryl) to help minimize side effects. They will also continue to take prednisone by mouth on days 2, 3, 4, and 5. On Day 4, the patient will receive another dose of VELCADE.
  • Before the beginning of every cycle of study treatment, the following will be performed: Medical history; physical examination; and routine blood tests. After the 3rd and 6th cycle of study treatment, the patient will have tests to monitor the status of their disease. These include PET scan, CT scans, and standard blood tests.
  • After 6 cycles of chemotherapy, approximately 3 weeks of radiation therapy will begin. One month after completing radiation therapy, the patient will return to the clinic for a physical exam and blood tests. One month later, the following evaluations will occur: PET and CT scans; medical history; physical exam; routine blood tests.
  • There will be follow-up visits every 3 months for two years after the study treatment is completed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of CHOP/Rituxan Plus VELCADE in Mediastinal Large B-cell Lymphoma
Study Start Date : July 2006
Actual Primary Completion Date : November 2007
Actual Study Completion Date : May 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma
Drug Information available for: Bortezomib

Intervention Details:
  • Drug: bortezomib
    Given intravenously on day 1 and day 4 of a 21-day cycle for 6 cycles
    Other Name: Velcade
  • Drug: Rituximab
    Given intravenously on day 1 of a 21-day cycle for 6 cycles
  • Drug: Cyclophosphamide
    Given intravenously on day 1 of a 21-day cycle for 6 cycles
  • Drug: Doxorubicin
    Given intravenously on day 1 of a 21-day cycle for 6 cycles
  • Drug: Vincristine
    Given intravenously on day 1 of a 21-day cycle for 6 cycles
  • Drug: Prednisone
    Taken orally on days 2, 3, 4 and 5 or a 21-day cycle for 6 cycles
  • Radiation: Radiation therapy
    After 6 cycles of chemotherapy there will be 3 weeks of radiation therapy

Primary Outcome Measures :
  1. To evaluate the rate of complete response to therapy defined as resolution of PET avidity in all previously documented sites at the completion of chemotherapy. [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Assess toxicity [ Time Frame: 1 year ]
  2. evaluate event-free survival at 2 years [ Time Frame: 2 years ]
  3. evaluate overall survival at 2 years [ Time Frame: 2 years ]
  4. assess early PET restaging after 3 cycles of chemotherapy. [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
  • Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (ie, a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study.
  • Male subject agrees to use an acceptable method for contraception for the duration of the study.
  • Histologic Documentation: Histologically confirmed Primary Mediastinal Large B-cell Lymphoma with confirmatory immunoperoxidase stains including TRAF-1, and nuclear c-rel. All cases must be reviewed at Brigham and Women's Hospital.
  • Previously untreated patients with the exception of limited radiotherapy or steroids for SVC syndrome
  • Age > 18 years of age
  • Measurable Disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥20 mm with conventional techniques or as ≥10 mm with spiral CT scan.

Exclusion Criteria:

  • Patient has a platelet count of < 100,000/uL within 14 days before enrollment.
  • Patient has an absolute neutrophil count of < 1500/uL within 14 days before enrollment.
  • Patient has a calculated or measured creatinine clearance of <30 mL/minute within 14 days before enrollment.
  • Patient has ³Grade 2 peripheral neuropathy within 14 days before enrollment.
  • Myocardial infarction within 6 months prior to enrollment or has New York Hospital Association (NYHA) Class III or IV heart failure (see section 8.4), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant.
  • Patient has hypersensitivity to bortezomib, boron or mannitol.
  • Female subject is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum b-human chorionic gonadotropin (b-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women.
  • Patient has received other investigational drugs with 14 days before enrollment
  • Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
  • Patient has a cardiac ejection fraction < 50% by echocardiogram or MUGA scan

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00361621

Layout table for location information
United States, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Millennium Pharmaceuticals, Inc.
Layout table for investigator information
Principal Investigator: Ann LaCasce, MD Dana-Farber Cancer Institute

Layout table for additonal information
Responsible Party: Ann S. LaCasce, MD, Assistant Professor of Medicine, Dana-Farber Cancer Institute Identifier: NCT00361621     History of Changes
Other Study ID Numbers: 06-012
First Posted: August 8, 2006    Key Record Dates
Last Update Posted: December 3, 2012
Last Verified: October 2009
Keywords provided by Ann S. LaCasce, MD, Dana-Farber Cancer Institute:
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antineoplastic Agents, Immunological
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Anti-Inflammatory Agents